Latest News and Press Releases

Study open for enrollment and patient screening underway at Stanford University Company expects first patient to be treated in the first quarter of 2020 EB-101 manufactured at Abeona facility in...

NEW YORK and CLEVELAND, Dec. 24, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the closing of its underwritten...

FDA removes clinical hold; Company may proceed with VIITAL™ study Company expects to initiate study in the first quarter of 2020 Primary endpoint confirmed as proportion of wounds with greater than...

Submitted additional EB-101 transport stability data to FDA in response to Clinical Hold Letter; CMC clearance for pivotal VIITALTM Phase 3 trial anticipated in Q4 2019Publication of positive...

CMC work completed in advance of EB-101 Phase 3 VITAL™ trial expected to begin mid-2019 IND submitted for ABO-202 in CLN1 disease Investor conference call on Tuesday, May 14 at 10:00 a.m. ET NEW...

NEW YORK and CLEVELAND, May 08, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that long-term follow up data...

-- The Elisa Linton Center for Rare Disease Therapies to support development of advanced gene and cell therapies for treatment of serious rare diseases -- Ribbon-cutting ceremony of gene and cell...

NEW YORK and CLEVELAND, May 08, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical- stage biopharmaceutical company focused on developing novel cell and gene...

First gene therapy RMAT designation for Epidermolysis BullosaEnables accelerated approval path and real world data usage NEW YORK and CLEVELAND, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Abeona...

--Strategic alignment with Brammer Bio for commercial AAV process development, scale up and assay validation --Phillip B. Maples, Ph.D., to lead Abeona manufacturing, as VP of Therapeutics...